Clinical Experiences with Fast Antibiotic Susceptibility Testing
Benefits of Attending
In addition to a brief technology overview of the Accelerate Pheno™ system, attendees will hear presentations from two District General Hospitals, one UK based and one Ireland based, on the potential impact of rapid diagnostics, in their institutions, to: • Escalate to effective therapy sooner • Optimise and de-escalate therapy earlier • Improve patient outcomes and reduce healthcare costs • Support antimicrobial stewardship and infection control efforts • Reduce antibiotic resistance
Summary
Chair’s session and speaker introduction: Dr. Nick Cortes, Consultant Microbiologist, Clinical Lead Microbiology, Hampshire Hospitals NHS Foundation Trust • Technology overview – Beyond Empirical Therapy: Steve Holland, Managing Director UK&I, Accelerate Diagnostics • Evaluation of the Accelerate Pheno™ blood culture system for rapid identification and antimicrobial susceptibility testing and comparison with conventional laboratory testing: Maria Molloy, Senior Medical Scientist, Microbiology Laboratory, University Hospital Galway. • Clinical Experiences of the Accelerate Pheno™ System at an NHS District General Hospital: Dr. Nick Cortes, Consultant Microbiologist, Clinical Lead Microbiology, Hampshire Hospitals NHS Foundation Trust Chair’s closing remarks and Q&A
Speakers
Steve Holland Managing Director, UK, and Ireland
Ken Muckle Key Account Manager, UK
Torsten Wassermann Clinical Development Specialist
-
Company
Accelerate Diagnostics